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Abstract
Background: Combination therapy with deferoxamine and oral deferiprone is superior to deferoxamine alone in
removing cardiac iron and improving left ventricular ejection fraction (LVEF). The right ventricle (RV) is also affected
by the toxic effects of iron and may cause additional cardiovascular perturbation. We assessed the effects of
combination therapy on the RV in thalassaemia major (TM) using cardiovascular magnetic resonance (CMR).
Methods: We retrieved imaging data from 2 treatment trials and re-analyzed the data for the RV responses: Trial 1
was a randomized controlled trial (RCT) of 65 TM patients with mild-moderate cardiac siderosis receiving
combination therapy or deferoxamine with placebo; Trial 2 was an open label longitudinal trial assessing
combination therapy in 15 TM patients with severe iron loading.
Results: In the RCT, combination therapy with deferoxamine and deferiprone was superior to deferoxamine alone
for improving RVEF (3.6 vs 0.7%, p = 0.02). The increase in RVEF was greater with lower baseline T2* 8-12 ms (4.7
vs 0.5%, p = 0.01) than with T2* 12-20 ms (2.2 vs 0.8%, p = 0.47). In patients with severe cardiac siderosis,
substantial improvement in RVEF was seen with open-label combination therapy (10.5% ± 5.6%, p < 0.01).
Conclusions: In the RCT of mild to moderate cardiac iron loading, combination treatment improved RV function
significantly more than deferoxamine alone. Combination treatment also improved RV function in severe cardiac
siderosis. Therefore adding deferiprone to deferoxamine has beneficial effects on both RV and LV function in TM
patients with cardiac siderosis.
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Background
In transfusion-dependent thalassaemia major (TM)
patients, iron chelation therapy is mandatory to prevent
or reverse iron accumulation caused by excess intake
from transfusional iron and the increased gastrointest-
inal absorption. Deferoxamine was the first clinically
available iron chelating agent, introduced over 40 years
ago, and life expectancy in TM increased dramatically
with its use. [1,2] However, its beneficial effects are tem-
pered by the cumbersome treatment regimes required,
which may be a contributor to the frequently observed
long term complications of heart failure and cardiac
death. [3]
Deferiprone is an orally active chelator with a lower
molecular weight that is uncharged at physiological pH,
and which is both hydrophilic and lipophilic enabling it
to readily penetrate myocardial cells. It has been shown
to be superior to deferoxamine in removing iron from
the myocardium, and is associated with improved car-
diac outcomes. [4-9] Due to differences in their access
to body iron pools, the use of a combination of the two
chelators seems to have a synergistic effect on removal
of excess iron. [9,10] A recent randomised controlled
trial comparing combination therapy with subcutaneous
deferoxamine and oral deferiprone against deferoxamine
monotherapy showed combination treatment to be
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ventricular ejection fraction (LVEF). [11] The beneficial
effects of combination therapy on LVEF have also been
confirmed in patients with TM and severe iron loading.
[12]
However, despite this success for LV function, the
importance of combination therapy on right ventricular
(RV) function has not been reported, even though the
RV can be affected by the toxic effects of myocardial
iron. [13,14] Cardiovascular magnetic resonance (CMR)
provides highly reliable and reproducible measurements
of RV volumes and function as well as myocardial iron
using the T2* method. [15,16] We therefore compared
the effects of combination treatment (deferoxamine and
deferiprone) with deferoxamine monotherapy on RV
function in TM patients with cardiac iron overload.
Methods
Study population
In order to examine the effects of combination treat-
ment on the RV, we reanalyzed imaging data from 2
previously reported trials. The first was a randomized,
double-blind, placebo controlled trial (RCT) comparing
combined therapy of deferoxamine with deferiprone
against deferoxamine with placebo in mild-moderate
myocardial siderosis. [11] The second trial was a longi-
tudinal open-label study of combination treatment (no
comparison arm) in patients with severe cardiac sidero-
sis and impaired LV function. [12] Both trials were run
simultaneously in Cagliari Italy (Figure 1). The study
protocol was approved by ethics committees in London
and Cagliari. Patient information and consent forms
were in Italian and all patients gave written informed
consent. [11,12] Brief details of the trials are given
below.
In the RCT, 167 adult TM patients (75 males, mean
age 30 ± 5.3 years) were screened for quantification of
myocardial iron loading using myocardial T2*. Inclusion
criteria for patient screening were: diagnosis of TM cur-
rently maintained on subcutaneous deferoxamine mono-
therapy; age > 18 years; and maintaining pre-transfusion
haemoglobin > 9 g/dL. Exclusion criteria were: patients
who had received deferiprone for a total of > 6 months
over the last 5 years; patients with previous reaction to
deferiprone; neutropenia (absolute neutrophil count <
1.5 × 10
9/L) at screening; thrombocytopenia ( < 50
×10
9/L) at screening; liver enzymes > 3 times upper
limit of normal; any condition making CMR impossible
or inadvisable. Of the 167 patients screened, 108 had
significant myocardial siderosis (T2* < 20 ms), of whom
22 (13%) had severe myocardial loading (T2* < 8 ms).
Patients with mild to moderate cardiac iron loading who
satisfied the trial entry criteria (myocardial T2* 8-20 ms,
n = 86) were invited for further detailed assessment by
CMR. Of these, 65 were subsequently randomized to
receive either deferoxamine plus deferiprone (combined
group; n = 32) or deferoxamine plus placebo (deferoxa-
mine group; n = 33), and were followed-up for 12
months.
Patients with severe cardiac siderosis (T2* < 8 ms)
were excluded from the RCT and it was at the treating
clinician’s discretion to determine best clinical practice
for chelation therapy. Of the 22 patients with severe
myocardial siderosis, 15 (9 females, 28.9 ± 4.8 years)
received open-label combination therapy according to
locally developed protocols, and were followed prospec-
tively over one year. These patients were used in a sec-
ondary comparative analysis against patients from the
randomised trial who were on combination therapy.
Cardiovascular magnetic resonance
A mobile 1.5 Tesla CMR scanner (Sonata, Siemens
Medical Systems, Erlangen, Germany) was transported
to Cagliari for this research. Myocardial and hepatic T2*
were assessed using the bright-blood single breath-hold
multi-echo technique as previously described. [17] T2*
analysis was performed using Thalassaemia-Tools (a
plug-in of CMRtools, Cardiovascular Imaging Solutions,
London, UK) with curve truncation to account for back-
ground noise. [18] Right ventricular volumes and ejec-
tion fraction were determined at baseline and at 12
months of treatment with steady state free precession
cines using contiguous short-axis slices from base to
apex. [15] CMRtools was used for RV volume analysis.
These measurements were performed by observers
blinded to the patient’s clinical details and chelation
regime.
Echocardiography
Doppler echocardiography studies were performed at
baseline and at 12 months to look for pulmonary hyper-
tension. Pulmonary artery systolic pressures (PAP) were
determined by peak velocity of the tricuspid regurgita-
tion jet plus estimation of right atrial pressures using
standard methodology. Pulmonary hypertension was
defined as PAP > 40 mmHg.
Biochemistry
Laboratory measures included weekly full blood count
(due to the risk of agranulocytosis with deferiprone),
serum ferritin (Abbott AXSYM System), B-type
natriuretic peptide (BNP-Biosite Diagnostics Inc, San
Diego, California), and liver function tests (alanine ami-
notransferase - ALT).
Statistical Analysis
Categorical data are presented as frequency and percen-
tage (%). Continuous variables are presented as mean ±
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played in median and interquartile range; and for T2*
and ferritin, which use the geometric mean (anti-log of
the mean of the log data) ± coefficient of variation (CV).
Baseline characteristics of both treatment groups were
compared using an unpaired two-tailed t-test for contin-
uous variables (except for BNP, which was compared by
a non-parametric test) and a chi-squared test for catego-
rical variables. Analysis of variance (ANOVA) was used
to compare changes in T2* and RVEF over 12 months
with treatment and baseline measures entered as covari-
ates. Changes in RVEF over 12 months within individual
groups were compared with a paired t-test. Correlations
of myocardial T2* with ventricular function were per-
formed using the Spearman’s rank test. Subgroup analy-
sis was performed according to severity of myocardial
iron loading with cut-offs of 8 ms and 12 ms used to
define patients with mild (T2* 12-20 ms), moderate (T2*
8-12 ms) and severe (T2* < 8 ms) iron loading. Intraob-
server and interobserver variability was assessed using
the method of Bland and Altman. [19] The coefficient
of variability was calculated as the SD of the differences
between two sets of measurements divided by the mean
value of the parameter under consideration. Statistical
significance was set at p < 0.05. All statistical analysis
was performed using Stata 10.1 software (StataCorp,
Texas, USA).
Results
RCT in mild to moderate cardiac siderosis
The baseline findings and the results of the RCT com-
paring combination treatment against deferoxamine
alone for changes in myocardial T2* and LV EF have
been previously published,[11] and are briefly summar-
ized here (table 1). The patients randomized to combi-
nation therapy or deferoxamine alone were evenly
Figure 1 Study flow-chart.
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in the combination arm was 75 mg/kg/day. The average
dose of deferoxamine in the deferoxamine alone arm
(40.5 mg/kg/day for 5 days/week) was comparable to
the combination arm (40.6 mg/kg/day for 5 days/week,
p = 1.0). Four patients in the combination arm withdrew
from the study (3 due to adverse events), and 3 patients
in the deferoxamine arm withdrew (1 due to an adverse
event). Thus, 28 patients in the combination arm and 30
patients in the deferoxamine alone arm completed the
study. Over 12 months, the combination treatment
group showed superior improvement in myocardial T2*
compared with the deferoxamine group (ratio of change
in geometric means 1.50 vs. 1.24, p = 0.02).
In the combination group RVEF increased from 60.2 ±
7.2% at baseline to 63.8 ± 5.9% at 12 months (p < 0.01),
whereas in the deferoxamine group RVEF did not
change significantly (61.0 ± 7.1% at baseline vs. 61.7 ±
6.4% at 12 months, p = 0.49). There was a significant
difference in the RVEF response between groups favour-
ing combination therapy (3.6 vs. 0.7%, p = 0.02; Figure
2). The improvement in RVEF in the combined group
was mainly driven by a decrease in RV end-systolic
volumes (52.5 ± 17.5 ml to 46.4 ± 14.9 ml, p < 0.01)
rather than a change in RV end-diastolic volumes (129.5
± 30.8 ml to 126.1 ± 29.8 ml, p = 0.20). There was no
significant change in PAP between the combination vs.
the deferoxamine arm from baseline to one year (-1.8
mmHg vs. +0.3 mmHg, p = 0.19).
The median myocardial T2* in the RCT at baseline
was 12.0 ms. This value was used as a cut-off to define
patients with mild (myocardial T2* 12-20 ms) and mod-
erate iron loading (myocardial T2* 8-12 ms), and this
was in accord with the cut-offs used in the original
trials. Both subgroups were then analysed according to
the chelation regime. Comparing the individual treat-
ment arms, we observed a significant improvement in
RVEF in patients with T2* between 8 and 12 ms on
Table 1 Baseline characteristics of the randomized controlled trial population, according to treatment arm.
Combined Deferoxamine p-value
Number of patients 32 33 -
Age (years) 28.8 ± 4.2 28.7 ± 5.3 0.9
Gender (male) 14 (44%) 13 (39%) 0.5
Body surface area 1.53 ± 0.15 1.56 ± 0.16 0.5
Heart rate 78 ± 10 81 ± 16 0.3
Deferoxamine dose (mg/kg/day) 40.6 ± 13.2 (5 days/week) 40.5 ± 14.0 5 days/week) 1.0
CMR measures
Myocardial T2* 11.7 (0.08) 12.4 (0.11) 0.3
Liver T2* 4.9 (0.52) 4.2 (0.62) 0.5
RVEDV (mL) 129.5 ± 30.8 131.8 ± 34.4 0.8
RVESV (ml) 52.5 ± 17.5 52.3 ± 18.5 1.0
RVEF (%) 60.2 ± 7.2 61.0 ± 7.1 0.7
Echo measures
PAP (mmHg) 22.3 ± 5.0 20.9 ± 5.4 0.4
Blood measures
Transfusional red blood cell input (mL/kg/year) 133.4 ± 34.9 130.2 ± 38.6 0.7
Haemoglobin (g/L) 106 ± 9.6 102 ± 9.5 0.1
Hepatitis C positive 23 (72%) 26 (79%) 0.4
Serum ferritin (μg/L) 1574 (11) 1379 (10) 0.5
BNP (pmol/L) 13.6 (5.6, 30.1) 15.2 (7.3, 26.2) 0.7
Creatinine (mg/dL) 0.77 ± 0.21 0.74 ± 0.23 0.6
Cardiac medication
Any 5 (16%) 8 (24%) 0.4
Digoxin 3 (9%) 4 (12%) 0.7
ACEi/ARB 5 (16%) 8 (24%) 0.4
Diuretics 3 (9%) 5 (15%) 0.5
Values are presented as n (%), mean ± SD, geometric mean (coefficient of variation), or as median (25
th -7 5
th percentile). RV = right ventricular; EDV = end-
diastolic volume; ESV = end-systolic volume; PAP = pulmonary artery systolic pressure; BNP = B-type natriuretic peptide. ACEi = angiotensin-converting enzyme
inhibitors; ARB = angiotensin II receptor blockers.
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6.0% at 12 months, p < 0.01), and borderline significant
improvement in patients with T2* between 12 and 20
ms (62.1 ± 7.3% at baseline vs. 64.3 ± 6.0% at 12
months, p = 0.08). Conversely, patients on deferoxamine
alone had no significant improvement in RVEF, whether
the baseline T2* was 8-12 ms (59.3 ± 6.8% at baseline
vs. 59.8 ± 6.4% at 12 months, p = 0.70) or 12-20 ms
(62.5 ± 7.2% at baseline vs. 63.3 ± 6.1% at 12 months, p
= 0.58). Comparison of the between groups effects
showed that combination therapy was superior to defer-
oxamine alone in improving RVEF in patients with base-
line T2* below 12 ms (4.7% vs. 0.5%, p = 0.01) but not
in those with T2* above 12 ms (2.2% vs. 0.8%, p = 0.47;
Figure 3).
Intraobserver and interobserver variability of the right
ventricular volumes and ejection fraction was derived
from the first 20 subjects participating in the study
(table 2). The coefficient of variability for the right
ventricular measurements was small, in keeping with
previous publications on the same area. [20,21]
Longitudinal open-label study in severe cardiac siderosis
The baseline findings and the results of the longitudinal
study in the 15 patients with severe iron loading (myo-
cardial T2* < 8 ms) evaluating combination treatment
for changes in myocardial T2* and LVEF have been pre-
viously published,[12] and are briefly summarized in
table 3. Two patients were in clinical heart failure, and
both had BNP levels > 100 pmol/l. The mean prescribed
doses of deferoxamine and deferiprone at baseline were
38.0 mg/kg for 5.3 days/week (equivalent to 40.7 mg/kg
for 5 days/week) and 73.9 mg/kg/day, respectively. Dur-
ing the trial, doses were reduced to 20.3 mg/kg for 4.5
days/week and 65.7 mg/kg/day respectively, primarily
due to reductions in ferritin. [11] All 15 patients
received unblinded combination therapy with deferoxa-
mine and deferiprone throughout the study period. Over
Figure 2 Change in myocardial T2* (left panel) and in RVEF (right panel) over 12 months according to treatment arm. Vertical lines
represent standard error.
Figure 3 Change in RVEF over 12 months according to treatment arm and myocardial T2* at baseline (T2* 8-12 ms on left panel, T2*
12-20 ms on right panel). Vertical lines represent standard error.
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cardial T2* (ratio of change in geometric means 1.31, p
< 0.01).
In 12 of the 15 patients (80%), the baseline RVEF
was low compared to a reference TM population with
a normal T2*. [22] The baseline RVESV was signifi-
cantly raised and there was a trend for a higher
RVEDV, resulting in a significantly reduced mean
RVEF (49.0 ± 9.4%) when compared to the population
with less severe iron loading (table 2). The open-label
group was more frequently medicated for heart failure,
particularly angiotensin-converting enzyme inhibitors
(ACEi)/angiotensin II receptor blockers (ARB). No
patients in the RCT or open-label cohorts were on
beta-blockers. Pulmonary artery systolic pressures were
similar in both groups (22.0 ± 5.9 mmHg vs 21.6 ± 5.2
mmHg, p = 0.82). Over 12 months, there was a signifi-
cant improvement in RVEF (10.5 ± 5.6%, p < 0.01),
with no significant change in PAP (22.0 mmHg vs 24.4
mmHg at 12 months, p = 0.16). No new cardiac medi-
cations were commenced during the study (except for
the 2 patients presenting with heart failure, who were
asymptomatic by the end of the study). Despite a posi-
tive trend, neither cardiac medication as a whole
( i n c r e a s eR V E F1 2±6 %v s9±5 % ,p=0 . 2 ) ,n o ri n d i -
vidual medications (digoxin: 14 ± 3% vs 10 ± 6%, p =
0.2; ACEi/ARB: 12 ± 6% vs 9 ± 5%, p = 0.2; diuretics:
13 ± 5% vs 10 ± 6%, p = 0.4) were significantly asso-
ciated with a higher increase in RVEF compared with
those without cardiac medication.
When grouping the patients on combination therapy
(the 32 patients from the combination arm in the RCT
plus the 15 unblinded patients on open-label combined
therapy), we found an inverse relation between myocar-
dial T2* at baseline and improvement in RVEF over one
year (Figure 4). Patients with severe iron loading had a
greater improvement in RVEF than patients with mod-
erate iron loading (10.5% vs. 4.7%, p < 0.01).
Entire study cohort
In the cohort of 80 patients with myocardial iron load-
ing, a significant correlation was observed between base-
line myocardial T2* and baseline RVEF (r = 0.46, p <
0.01) and baseline LVEF (r = 0.50, p < 0.01). Accord-
ingly, there was a strong correlation between RVEF and
LVEF at baseline (r = 0.82, p < 0.01). The improvement
in RVEF during the study period also correlated with
the improvement in LVEF (r = 0.79, p < 0.01; Figure 5).
We also analyzed the change in RVEF with the change
in cardiac iron as derived from recent human cardiac
iron calibration data from Carpenter et al. [23] There
was a significant inverse correlation between the
improvement in myocardial iron concentration and the
improvement in RVEF (r = -0.42, p < 0.01).
Table 2 Intraobserver and interobserver reproducibility for the right ventricle.
Intraobserver Interobserver
Mean difference (± SD) CoV (%) Mean difference (± SD) CoV (%)
RV end-diastolic volume (mL) 0.6 ± 5.0 3.9 6.7 ± 8.9 7.1
RV end-systolic volume (mL) -0.1 ± 3.6 6.7 2.0 ± 4.7 8.9
RV ejection fraction (%) 0.5 ± 1.9 3.2 1.0 ± 3.0 5.2
CoV = coefficient of variability; RV = right ventricle.
Table 3 Baseline characteristics of the randomized
controlled trial population (mild and moderate
myocardial iron loading) vs. open-label combination
therapy population (severe myocardial iron loading).
Values and abbreviations presented as in table 1.
Mild-moderate
siderosis
Severe
siderosis
p-
value
RCT Longitudinal
trial
Number 65 15 -
Age (years) 28.8 ± 4.7 27.8 ± 4.8 0.5
Gender (male) 27 (41.5%) 6 (40.0%) 0.9
Body surface area 1.55 ± 0.15 1.56 ± 0.13 0.8
Heart rate 79 ± 13 97 ± 18 < 0.01
Deferoxamine (mg/kg/
day)
40.6 ± 13.5
(5 days/week)
40.7 ± 12.0
(5 days/week)
0.9
CMR measures
Myocardial T2* 12.0 (0.13) 6.0 (0.09) N/A
Liver T2* 4.5 (0.57) 2.9 (0.67) 0.06
RVEDV (mL) 130.7 ± 32.4 146.7 ± 35.1 0.2
RVESV (mL) 52.4 ± 17.8 76.5 ± 27.6 < 0.01
RVEF (%) 60.6 ± 7.1 49.0 ± 9.4 < 0.01
Echo measures
PAP (mmHg) 21.6 ± 5.2 22.0 ± 5.9 0.8
Blood measures
Hepatitis C positive 49 (75%) 11 (73%) 0.9
Serum ferritin (μg/L) 1472 (0.11) 2057 (0.08) 0.1
BNP (pmol/L) 15.0 (7.1, 28.8) 26.0 (15.6, 40.5) 0.01
Cardiac medication
Any 13 (20%) 7 (47%) 0.03
Digoxin 7 (11%) 4 (27%) 0.1
ACEi/ARB 13 (20%) 7 (47%) 0.03
Diuretics 8 (12%) 4 (27%) 0.2
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Vertical lines represent standard error.
Figure 5 Correlation of change in RVEF with change in LVEF over 12 months.
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With the development of the T2* technique, CMR has
provided new insights into iron-overload cardiomyopa-
thy, as the myocardial iron concentration and its toxic
effect on ventricular function can be assessed at the
same time with the same high-fidelity technique. In the
first T2* publication by Anderson et al, normal T2*
levels were associated with normal LVEF, but when T2*
fell below 20 ms, there was a progressive fall in LVEF,
showing that increasing iron loading is associated with
worsening of LV function. [16] Similar observations
have recently been made for the RV,[14] suggesting RV
dysfunction may be a contributor to heart failure and
cardiac mortality in TM patients, as has been found in
other cardiac conditions. [24-28] However, to date,
there has been little published data on the response of
the right ventricle to chelation therapy, and no data at
all on the most appropriate chelation regime in the pre-
sence of right ventricular dysfunction.
Chelation with deferoxamine has been one of the cor-
nerstones for the treatment of TM. It has been exten-
sively studied over the past decades and has shown to
decrease the total body iron burden, prevent complica-
tions of iron overload and improve survival in TM.
[1,2,29] However, long-term deferoxamine monotherapy
has been hampered by poor compliance and failure of
long term prevention of myocardial iron deposition,
heart failure and cardiac deaths. [4,5] Deferiprone is a
more recent iron chelator which has a lower molecular
weight, is more lipophilic, is uncharged at physiologic
pH and consequently appears better able to penetrate
cells and organelles than deferoxamine. This may in
part explain why deferiprone is superior to deferoxa-
mine for removing iron from the heart. [6] The com-
bined use of these two chelating agents which exploits
the relative merits of each drug, has been supported in
animal models, and has become an attractive therapeutic
option in severe cardiac iron loading or when negative
iron balance has not been achieved by other methods.
[11,30,31] Observational, prospective and randomised
controlled studies have demonstrated the efficacy of
combined therapy in removing iron from the liver and
heart, improving endothelial function and left ventricu-
lar function,[11,12] as well as endocrine function. [32]
Our current study compared the effects of combination
therapy on RV function in TM patients with myocardial
iron loading. Our findings from the RCT show combi-
nation therapy to be superior to subcutaneous deferoxa-
mine alone in improving RV function in patients with
mild and moderate iron loading. In addition, our data
from the longitudinal open-label study show that RV
d y s f u n c t i o ni sr e v e r s i b l ee v e ni np a t i e n t sw i t hs e v e r e
iron overload. It is of interest that the recovery in RV
function was greatest in patients with a more severe
degree of myocardial siderosis and RV dysfunction.
It is well recognized that RV performance depends not
only on intrinsic contractility but also on RV afterload,
which is the resistance that the RV has to overcome
during ejection. Increased pulmonary artery pressures
reflecting increased pulmonary vascular resistance may
thus impair RV function. [33] However, none of the par-
ticipants in this study had pulmonary hypertension, in
line with previous studies suggesting a low prevalence of
pulmonary hypertension in TM. [34,35] Whilst an
improvement in myocardial T2* was associated with an
improvement in RVEF, no significant changes in pul-
monary artery pressures were observed throughout the
study. Therefore, the improvement in RV function seen
in this population was independent of pulmonary artery
pressure thus eliminating a potential confounding factor
for the evaluation of RV function.
Our data are unusual, because reversible RV dysfunc-
tion in the setting of a cardiomyopathy is a rarely docu-
mented phenomenon. The magnitude of recovery in RV
function parallels the recovery in LV function, and this
correlates with the response to chelation therapy. This
is in keeping with the findings of other studies in non-
ischaemic cardiomyopathies, where it has been observed
that LV and RV function is usually affected in a similar
way and to a similar extent. [24,36] The close associa-
tion seen between RVEF and LVEF and the increase of
these parameters over time following successful myocar-
dial iron chelation supports the concept that intrinsic
RV myocardial contractility is predominantly affected by
intracellular iron and plays a key role in RV perfor-
mance in this toxic-induced cardiomyopathy model. [14]
Finally, as right ventricular ejection fraction has incre-
mental prognostic value which is additional to LVEF,
[24-27] it is reasonable to suggest that the improvement
in RVEF seen in this study with the combined use of
deferiprone and deferoxamine may contribute to
improved outcomes.
Limitations
This is a retrospective analysis of 2 trials designed to
assess the change on myocardial T2* with iron chelation
regimes in which RV parameters were not planned as
primary end-points. Nevertheless, all data was prospec-
tively collected and the current RV analysis was blinded
to the patients’ details and chelation regimes.
Conclusions
In the RCT of mild to moderate cardiac iron loading,
combination treatment improved RV function signifi-
cantly more than deferoxamine alone. Combination
treatment also improved RV function in severe cardiac
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has beneficial effects on both RV and LV function in
TM patients with cardiac siderosis.
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